Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola (EBOVAC3DRC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04186000
Recruitment Status : Recruiting
First Posted : December 4, 2019
Last Update Posted : January 18, 2020
Johnson & Johnson
Ace Africa
Innovative Medicines Initiative
Coalition for epidemic prepardness innovations
University of Kinshasa
Information provided by (Responsible Party):
Pierre Van Damme, Universiteit Antwerpen

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : July 18, 2022
Estimated Study Completion Date : December 18, 2022
Publications of Results: